A Phase I Trial Of Andrographolide In HIV Positive Patients And Normal Volunteers
| 効果 | 増加 |
| 試験方法 | コホート法 |
| 試験期間 | 不明 |
| 被験者数 | 17 |
| 性別 | 不明 |
この研究の注釈：
Andrographolide at up to 30mg daily failed to influence the amount of the HIV virus in persons with HIV and increased serum liver enzymes, although it acted to normalize CD4+ T-cells (suppressed in persons with HIV). In a small cohort of persons without HIV, CD4+ T-cells were reduced.